查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1862931

多重检测免疫检测市场：按技术、产品、最终用户和应用划分 - 全球预测（2025-2032 年）

Multiplex Detection Immunoassays Market by Technology, Product, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，多重检测免疫检测市场将成长至 39.1 亿美元，复合年增长率为 7.12%。

主要市场统计数据
基准年 2024 22.5亿美元
预计年份：2025年 24.1亿美元
预测年份：2032年 39.1亿美元
复合年增长率 (%) 7.12%

关于多重检测免疫检测的权威报告：技术整合、临床应用和相关人员期望塑造策略重点的框架

多重检测免疫检测技术已发展成为现代转化研究、临床诊断和治疗开发的基础。检测小型化、试剂化学和数据分析技术的进步，使得从极少量样本中同时检测多种分析物成为可能，在提高通量的同时，也保留了生物学背景资讯。这些技术对于生物标记发现、免疫分析和多重临床检测至关重要，因为多维度的结果可以提高诊断特异性，并对患者群体进行分层，从而指导标靶治疗。

技术整合、工作流程整合和生态系统协作将如何重新定义多重免疫检测领域的竞争格局和应用管道

过去五年，在技术创新融合和终端用户需求变化的推动下，多重检测免疫检测领域经历了变革性发展。从单分析物检测到高密度微珠、平面阵列和微阵列技术的转变，加速了该技术从研发阶段到临床应用的进程。基于流式细胞技术的系统和以微珠为基础的平台的改进提高了灵敏度和动态范围，而微阵列和平面阵列技术则实现了高密度探针架构，从而能够在有限的样本量内捕获更广泛的分析物特征。

评估截至2025年的关税调整如何影响免疫检测价值链中的筹资策略、供应链韧性和生产本地化决策。

美国在2025年前实施的一系列贸易措施和关税调整，为多重免疫检测价值链中的供应商和终端用户带来了复杂的挑战。关税变化正在影响进口仪器、试剂盒和关键原材料的相对成本结构，进而影响製造商、经销商和临床检查室的筹资策略。采用地域多元化製造地和采购策略的供应商更有能力应对近期成本波动。同时，依赖单一区域供应链的公司正面临营运压力，迫使它们重新评估供应商合约并调整定价模式。

透过综合分析技术类型、产品系列、最终用户需求和临床应用，帮助确定打入市场策略。

要了解多重侦测免疫检测市场的模组化结构，就需要清楚了解定义竞争格局和应用场景边界的关键技术、产品、终端用户和应用维度。从技术角度来看，以微珠为基础的免疫检测、基于流式细胞技术的免疫检测、基于微阵列的免疫检测和平面阵列免疫检测之间的区别至关重要，因为每种形式在通量、灵敏度、多重密度和工作流程相容性方面都各有重点。这些技术选择会影响产品设计和下游服务需求。

影响美洲、欧洲、中东和非洲以及亚太地区采用、分销和监管管道的关键区域趋势和战略考量

区域趋势对多重免疫检测的技术应用、分销模式和监管管道产生了深远影响，美洲、欧洲、中东和非洲以及亚太地区呈现出截然不同的模式。在美洲，强大的学术网络、完善的临床检测基础设施和蓬勃发展的生物技术产业推动了新型检测方法和整合平台的早期应用。采购实践往往侧重于检验的工作流程和强大的售后支持，这促使供应商提供全面的服务包和本地化的技术支援。

深入了解推动差异化并在此领域创造整合价值提案的企业策略、伙伴关係模式和能力投资

多重免疫检测领域的竞争格局由仪器製造商、试剂专家、软体创新者和整合解决方案提供者组成，他们在整个价值链上既相互竞争又相互合作。领先的仪器供应商在分析性能、通量和整合便利性方面脱颖而出，而试剂和试剂盒供应商则专注于检测特异性、批间一致性和法规文件，以支援临床和研究应用。软体供应商和服务供应商在将原始检测结果转化为检验、可重复的洞察以及透过云端分析和强大的品管模组实现可扩展部署方面发挥着越来越重要的作用。

领导者需应对的实际策略挑战，以增强平台模组化、供应链韧性、监管准备和伙伴关係主导的商业化。

产业领导者应采取审慎措施，以增强自身竞争优势、推动产品应用并管控营运风险。首先，应优先开发模组化平台，实现逐步升级和不同检测方法之间的交叉相容。这有助于降低顾客转换成本，提升产品生命週期价值。模组化硬体结合检验的试剂盒和可互通的数据分析软体，将能够提供与终端用户工作流程相契合的差异化解决方案。

为了支持这些发现，我们采用了严谨的混合方法研究方法，结合了专家访谈、文献检验和跨区域检验，以得​​出可靠的研究结果。

支持这些发现的研究采用了多层次的调查方法，以确保结论的稳健性和可重复性。对主要技术文献、监管指南和已发表的临床检验研究进行全面回顾，为技术性能特征和应用适用性奠定了证据基础。此外，还对包括实验室主任、检测方法开发科学家、采购人员以及平台和试剂软体供应商的高级管理人员在内的利益相关人员进行了结构化的访谈，以了解实际运营情况和战略意图，从而补充了上述二手研究。

总之，我们的综合分析确定了多重解决方案可持续采用所需的关键组合：检验的性能、证据生成和营运弹性。

累积分析揭示了技术成熟度、临床需求和商业性结构调整的交汇点。多重检测免疫检测已从小众研究工具发展成为广泛适用的平台，支持药物发现、转化研究以及日益严苛的临床应用。技术多样性——以微珠为基础、流式细胞技术、微阵列和平面阵列的方法——为根据通量、灵敏度和检体限制定制解决方案指明了方向。同时，仪器、试剂盒和软体服务的产品细分也明确了商业化优势。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将微流体平台整合到照护现场诊断中，用于高通量多重免疫检测
  • 在临床研究中采用新型萤光条码技术同时检测多种细胞激素
  • 人工智慧驱动的数据分析软体的出现，增强了多重检测结果的解读和预测性生物标记的发现。
  • 利用磁性奈米粒子开发以微珠为基础的多重免疫检测方法，用于食品安全领域的病原体快速筛检
  • 标准化校准方法对于提高不同平台多重检测结果的重现性变得越来越重要。
  • 利用数位ELISA技术对多重检测中低表现蛋白生物标记进行超灵敏检测
  • 扩展单细胞多重免疫检测，以实现自体免疫疾病研究中全面的免疫分析
  • 在远端医疗环境中整合基于智慧型手机的成像模组，用于携带式多重免疫检测读数。
  • 生物技术公司与学术机构合作开发通用检测平台，该平台可容纳多种分析标靶。
  • 监管机构日益重视多重检测检验标准，以确保其临床效用和病人安全。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 多重检测免疫检测市场（依技术划分）

  • 以微珠为基础的免疫检测
  • 基于流式细胞技术的免疫检测
  • 基于微阵列的免疫检测
  • 平面阵列免疫检测测定

9. 多重检测免疫检测市场（依产品划分）

  • 装置
    • 分析器
    • 流式细胞仪
    • 领导者
  • 试剂盒和试剂
    • 检测珠
    • 检测抗体
    • 微阵列
    • 多重检测试剂盒
  • 软体和服务
    • 检测开发服务
    • 数据分析软体
    • 支援与维护

10. 多重检测免疫检测市场（依最终用户划分）

  • 学术研究机构
  • CRO（受託研究机构）
  • 医院和诊断实验室
  • 製药和生物技术公司

11. 多重检测免疫检测市场（按应用划分）

  • 自体免疫疾病
    • 发炎性肠道疾病
    • 类风湿性关节炎
    • 全身性红斑性狼疮
  • 心血管疾病
    • 动脉粥状硬化
    • 心臟衰竭
    • 高血压
  • 感染疾病
    • 细菌感染疾病
      • 大肠桿菌
      • 沙门氏菌
      • 结核
    • 寄生虫感染疾病
      • 疟疾
      • 血吸虫病
      • 弓形虫病
    • 病毒感染疾病
      • 肝炎
      • HIV
      • 流感
  • 神经病学
    • 阿兹海默症
    • 多发性硬化症
    • 帕金森氏症
  • 肿瘤学
    • 乳癌
    • 大肠直肠癌
    • 肺癌
    • 摄护腺癌

12. 各地区多重检测免疫检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 多重检测免疫检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国多重检测免疫检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Bio-Rad Laboratories, Inc.
    • Becton, Dickinson and Company
    • PerkinElmer, Inc.
    • Luminex Corporation
    • QIAGEN NV
    • Bio-Techne Corporation
    • Meso Scale Diagnostics, LLC
    • Olink Proteomics AB
Product Code: MRR-FF012EDC38B1

The Multiplex Detection Immunoassays Market is projected to grow by USD 3.91 billion at a CAGR of 7.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.25 billion
Estimated Year [2025] USD 2.41 billion
Forecast Year [2032] USD 3.91 billion
CAGR (%) 7.12%

An authoritative introduction to multiplex detection immunoassays framing technological convergence, clinical applications, and stakeholder expectations shaping strategic priorities

The multiplex detection immunoassays landscape has evolved into a cornerstone of modern translational research, clinical diagnostics, and therapeutic development. Advances in assay miniaturization, reagent chemistry, and data analytics have collectively enabled simultaneous measurement of multiple analytes from minimal sample volumes, improving throughput while preserving biological context. These technologies are increasingly integral to biomarker discovery, immunoprofiling, and multiplexed clinical panels where multidimensional readouts can refine diagnostic specificity and stratify patient populations for targeted therapies.

Today's users expect platforms that bridge rigorous analytical performance with operational efficiency. This expectation has driven instrument vendors, reagent suppliers, and service providers to iterate on assay formats and workflow integration, focusing on robustness, reproducibility, and scalability. Simultaneously, the emphasis on open data standards and interoperability has broadened the role of software and services that translate raw assay signals into clinically meaningful insights. As a result, the sector now sits at the intersection of diagnostics, life sciences research, and precision medicine, serving a diverse set of end users including academic research centers, contract research organizations, clinical laboratories, and pharmaceutical and biotechnology firms.

Given these dynamics, stakeholders must balance technical performance with commercialization considerations, regulatory pathways, and evolving application portfolios. The introduction sets the stage for a detailed examination of technological trajectories, segmentation nuances, regulatory and trade headwinds, and regional market dynamics that together shape near-term priorities and long-term strategic choices for organizations operating in this field.

How technological convergence, workflow integration, and ecosystem partnerships are redefining competitive dynamics and adoption trajectories in multiplex immunoassays

Over the past five years the multiplex detection immunoassays domain has undergone transformative shifts driven by converging technological innovations and changing end-user demands. Transition from single-analyte assays toward high-content bead, planar array, and microarray formats has accelerated adoption across discovery and clinical settings. Improvements in flow cytometry-based systems and bead-based platforms have enhanced sensitivity and dynamic range, while microarray and planar approaches have allowed denser probe architectures to capture broader analyte signatures within constrained sample volumes.

Parallel to hardware advances, the maturation of data analysis software and cloud-enabled workflows has made complex multiplex data more accessible to non-specialist laboratories. These software enhancements underpin reproducible analytics, automated quality control, and streamlined reporting-critical enablers for routine clinical adoption. Regulatory expectations have also shifted to emphasize assay validation pathways and traceability, prompting vendors to invest in higher-quality reagents, standardized protocols, and comprehensive documentation.

Another notable shift is the increasing prominence of partnerships and platform ecosystems. Instrument manufacturers are aligning with reagent providers, software developers, and contract research organizations to deliver integrated solutions that reduce time-to-result and lower operational barriers. This collaborative model supports rapid assay development and facilitates deployment across diverse end users, from academic labs to diagnostic service providers. Collectively, these shifts are reshaping competitive dynamics and creating new pathways for differentiation centered on end-to-end workflow value rather than singular component performance.

Assessing how tariff adjustments through 2025 have reshaped procurement strategies, supply chain resilience, and manufacturing localization decisions across the immunoassay value chain

The landscape of trade measures and tariff adjustments introduced by the United States through 2025 has introduced a layer of complexity for suppliers and end users in the multiplex detection immunoassays value chain. Tariff changes have affected the relative cost structure for imported instruments, assay kits, and critical raw materials, influencing procurement strategies across manufacturers, distributors, and clinical laboratories. Suppliers with geographically diversified manufacturing and sourcing strategies have fared better in mitigating immediate cost disruptions, while those reliant on single-region supply lines have faced operational pressure to rework supplier contracts and revisit pricing models.

These tariff-related dynamics have also prompted firms to accelerate localization strategies for production and assembly, enabling closer control over customs classifications and reducing exposure to fluctuating import duties. In response, some companies have implemented hybrid sourcing models that combine regional manufacturing for critical components with centralized high-tech assembly to preserve economies of scale. At the same time, contract research and diagnostic service providers have adjusted purchasing cadences and inventory policies to hedge against short-term cost volatility and delivery uncertainty.

Regulatory and procurement teams have increasingly emphasized total landed cost assessment and supplier resilience when evaluating capital equipment and reagent purchases. This has led to a greater focus on multi-year service agreements, modular upgrade paths for instruments, and supplier warranties that transfer certain risks back to manufacturers. In aggregate, the tariff environment through 2025 has elevated the strategic importance of supply chain configuration, procurement flexibility, and localized support capabilities for organizations operating across the multiplex immunoassays ecosystem.

Comprehensive segmentation analysis linking technology formats, product portfolios, end-user requirements, and clinical applications to inform prioritization and go-to-market choices

Understanding the modular architecture of the multiplex detection immunoassays market requires a clear articulation of the primary technology, product, end-user, and application dimensions that define competitive and use-case boundaries. From a technology perspective, distinctions between bead-based immunoassays, flow cytometry-based immunoassays, microarray-based immunoassays, and planar array immunoassays are fundamental because each format delivers a different balance of throughput, sensitivity, multiplexing density, and workflow compatibility. These technological choices in turn influence product design and downstream service requirements.

When examining products, the market segments into instruments, kits and reagents, and software and services. Instruments encompass analyzers, flow cytometers, and readers that form the hardware backbone of multiplex workflows. Kits and reagents include assay beads, detection antibodies, microarrays, and multiplex assay kits that determine the biochemical performance and specificity of assays. Software and services cover assay development services, data analysis software, and support and maintenance offerings that enable standardized operations and post-sale value capture. Each product category interacts with technology formats differently and necessitates tailored commercialization models.

End users of multiplex platforms span academic and research institutes, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies. These diverse user groups have distinct purchasing rationales, validation expectations, and throughput requirements, which influence product roadmaps and go-to-market approaches. Application areas further refine deployment priorities, with use cases across autoimmune conditions, cardiovascular disease, infectious diseases, neurological disorders, and oncology. Within these applications, subdomains such as inflammatory bowel disease, rheumatoid arthritis, Alzheimer's disease, multiple sclerosis, breast cancer, and viral infections like hepatitis and influenza dictate specific panel compositions, regulatory considerations, and clinical validation pathways. Mapping product capabilities to these segmented needs is essential for prioritizing development investments and commercial engagement strategies.

Key regional dynamics and strategic considerations across the Americas, Europe Middle East and Africa, and Asia-Pacific that influence adoption, distribution, and regulatory pathways

Regional dynamics exert a profound influence on technology adoption, distribution models, and regulatory pathways for multiplex detection immunoassays, with distinctive patterns emerging across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, strong academic networks, established clinical laboratory infrastructure, and a robust biotech sector drive early adoption of novel assays and integrated platforms. Procurement practices tend to favor validated workflows and extensive post-sale support, which incentivizes vendors to offer comprehensive service packages and localized technical assistance.

Europe Middle East and Africa present a heterogeneous environment where regulatory harmonization efforts in some jurisdictions coexist with fragmented reimbursement and procurement systems in others. This complexity amplifies the importance of tailored market entry strategies, partnerships with regional distributors, and investments in regulatory and clinical evidence generation that meet diverse national requirements. In contrast, Asia-Pacific markets exhibit rapid uptake of cost-effective platforms and point-of-care-enabling technologies, supported by growing domestic manufacturing capabilities and public-private collaborations that accelerate translational research and clinical deployment.

Across all regions, regional supply chain considerations, tariff regimes, and local validation expectations shape vendor strategies. Companies seeking to scale across multiple regions must reconcile variant regulatory demands with the need for consistent assay performance and interoperable data outputs. Consequently, regional market planning must integrate clinical engagement, distribution logistics, and post-market surveillance mechanisms to ensure sustainable adoption and long-term product stewardship.

Insights into company strategies, partnership models, and capability investments that are driving differentiation and creating integrated value propositions in the sector

The competitive landscape in multiplex detection immunoassays includes a mix of instrument manufacturers, reagent specialists, software innovators, and integrated solution providers that compete and collaborate across the value chain. Leading instrument providers differentiate on analytical performance, throughput, and ease of integration, while reagent and kit suppliers focus on assay specificity, lot-to-lot consistency, and regulatory documentation to support clinical and research use. Software vendors and service providers are increasingly central, transforming raw assay output into validated, reproducible insights and enabling scalable deployment through cloud analytics and robust quality management modules.

Partnership strategies are a recurring theme among successful companies. Collaborations between instrument manufacturers and reagent developers accelerate time-to-market for validated panels, while alliances with contract research organizations facilitate early-stage assay validation and broader clinical exposure. Strategic acquisitions have also played a role, enabling companies to vertically integrate critical capabilities such as proprietary chemistries, data analysis toolkits, and global distribution networks. Additionally, commercial models are diversifying, with subscription and service-based offerings complementing traditional capital equipment sales to spread adoption risk and create recurring revenue streams.

Operationally, successful firms emphasize regulatory readiness, supply chain flexibility, and comprehensive customer support. Investments in standardized quality systems, global service footprints, and local manufacturing or assembly capabilities help mitigate trade and logistics risks. Looking forward, companies that can demonstrate end-to-end value-combining robust instrumentation, high-quality reagents, and software-enabled analytics-will be best positioned to capture adoption when customers prioritize validated, workflow-oriented solutions over standalone components.

Actionable strategic imperatives for leaders to enhance platform modularity, supply chain resilience, regulatory readiness, and partnership-led commercialization

Industry leaders should pursue a deliberate set of actions to strengthen competitive positioning, accelerate adoption, and manage operational risk. First, prioritize modular platform development that enables incremental upgrades and cross-compatibility across assay formats; this reduces customer switching costs and increases lifetime value. Coupling modular hardware with validated reagent panels and interoperable data analysis software creates compelling, differentiated solutions that align with end-user workflows.

Second, fortify supply chain resilience by diversifying component sources and exploring regional manufacturing or assembly hubs to mitigate tariff exposure and logistics disruptions. Embedding dual sourcing for critical reagents and establishing strategic buffer inventories in key geographies will decrease lead-time vulnerability. Third, invest in regulatory and clinical evidence generation early in development cycles. Establish clear validation roadmaps that address jurisdictional differences and prioritize high-impact use cases, such as oncology and infectious disease panels, where clinical utility is demonstrable and adoption thresholds are clearer.

Fourth, cultivate ecosystem partnerships with reagent developers, software providers, clinical labs, and contract research organizations to accelerate assay validation and expand addressable applications. Co-development agreements and revenue-sharing models can help scale adoption while sharing development risk. Fifth, adopt flexible commercial models that blend capital sales with subscription-based analytics and service contracts, thereby aligning vendor incentives with successful long-term outcomes for customers. Finally, emphasize workforce training and customer support infrastructure to ensure that end users derive consistent, reproducible performance from multiplex platforms, reinforcing trust and reducing downstream support costs.

A rigorous mixed-methods research approach integrating primary expert interviews, secondary literature validation, and cross-regional triangulation to support defensible insights

The research underpinning these insights combined a layered methodological approach to ensure robust, reproducible conclusions. A comprehensive review of primary technical literature, regulatory guidance, and publicly available clinical validation studies established the evidence base for technology performance characteristics and application suitability. This secondary research was complemented by structured primary interviews with subject matter experts, including laboratory directors, assay development scientists, procurement leads, and senior executives from platform, reagent, and software providers to capture operational realities and strategic intent.

Data triangulation was employed to reconcile qualitative insights with documented product specifications, regulatory filings, and peer-reviewed study results. The methodological framework emphasized cross-validation of claims, focusing on repeatable findings such as assay workflow dependencies, reagent stability considerations, and software integration challenges. To ensure relevance across geographies, regional experts were consulted to identify jurisdiction-specific regulatory expectations, procurement practices, and supply chain vulnerabilities.

Limitations of the methodology are acknowledged transparently. Certain proprietary performance metrics and internal procurement data were unavailable for direct verification, and interviews reflect expert judgment which can vary by institution type and use case. Nonetheless, the combined use of primary expert input, secondary literature validation, and cross-regional perspective building provides a high-confidence foundation for the strategic and operational recommendations presented. Where appropriate, the report highlights areas where further primary data collection or controlled comparative studies would strengthen conclusions.

Concluding synthesis identifying the decisive combination of validated performance, evidence generation, and operational resilience required for sustainable adoption of multiplex solutions

The cumulative analysis reveals a field at the nexus of technological maturation, clinical need, and commercial reinvention. Multiplex detection immunoassays have transitioned from niche research tools to broadly applicable platforms capable of supporting discovery, translational research, and increasingly rigorous clinical applications. Technological diversity-spanning bead-based, flow cytometry-based, microarray-based, and planar array approaches-offers pathways to tailor solutions by throughput, sensitivity, and sample constraints, while product segmentation across instruments, kits and reagents, and software and services delineates clear commercialization levers.

External forces such as tariff developments and regional regulatory variation have elevated supply chain strategy and localized validation as determinants of near-term competitiveness. At the same time, software-driven analytics and service models are unlocking new routes to value capture by transforming complex assay outputs into actionable, reproducible insights for clinicians and researchers. Companies that integrate platform performance with end-to-end support, evidence generation, and flexible commercial models will be better positioned to win in diverse end-user environments ranging from academic labs to clinical diagnostic settings.

In sum, success will favor organizations that balance innovation with operational rigor: those that can demonstrate validated clinical utility, ensure consistent reagent quality, provide interoperable analytics, and maintain resilient supply and support systems. This balanced approach will enable stakeholders to capitalize on the promise of multiplex detection technologies while managing the practical challenges of deployment and scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of microfluidic platforms for high-throughput multiplex immunoassays in point-of-care diagnostics
  • 5.2. Adoption of novel fluorescent barcoding techniques for simultaneous detection of multiple cytokines in clinical research
  • 5.3. Emergence of AI-driven data analysis software to enhance multiplex assay interpretation and predictive biomarker discovery
  • 5.4. Development of bead-based multiplex immunoassays using magnetic nanoparticles for rapid pathogen screening in food safety applications
  • 5.5. Growing emphasis on standardized calibration methods to improve inter-lab reproducibility of multiplex assay results across platforms
  • 5.6. Utilization of digital ELISA technology for ultrasensitive detection of low-abundance protein biomarkers in multiplex panels
  • 5.7. Expansion of single-cell multiplex immunoassays enabling comprehensive immune profiling in autoimmune disease research
  • 5.8. Integration of smartphone-based imaging modules for portable multiplex immunoassay readouts in remote healthcare settings
  • 5.9. Collaboration between biotech companies and academic institutions to develop universal assay platforms compatible with diverse analyte panels
  • 5.10. Increasing regulatory focus on multiplex assay validation standards to ensure clinical utility and patient safety

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiplex Detection Immunoassays Market, by Technology

  • 8.1. Bead Based Immunoassays
  • 8.2. Flow Cytometry Based Immunoassays
  • 8.3. Microarray Based Immunoassays
  • 8.4. Planar Array Immunoassays

9. Multiplex Detection Immunoassays Market, by Product

  • 9.1. Instruments
    • 9.1.1. Analyzers
    • 9.1.2. Flow Cytometers
    • 9.1.3. Readers
  • 9.2. Kits And Reagents
    • 9.2.1. Assay Beads
    • 9.2.2. Detection Antibodies
    • 9.2.3. Microarrays
    • 9.2.4. Multiplex Assay Kits
  • 9.3. Software & Services
    • 9.3.1. Assay Development Services
    • 9.3.2. Data Analysis Software
    • 9.3.3. Support & Maintenance

10. Multiplex Detection Immunoassays Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Hospitals And Diagnostic Laboratories
  • 10.4. Pharmaceutical And Biotechnology Companies

11. Multiplex Detection Immunoassays Market, by Application

  • 11.1. Autoimmune
    • 11.1.1. Inflammatory Bowel Disease
    • 11.1.2. Rheumatoid Arthritis
    • 11.1.3. Systemic Lupus Erythematosus
  • 11.2. Cardiovascular
    • 11.2.1. Atherosclerosis
    • 11.2.2. Heart Failure
    • 11.2.3. Hypertension
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial Infections
      • 11.3.1.1. E Coli
      • 11.3.1.2. Salmonella
      • 11.3.1.3. Tuberculosis
    • 11.3.2. Parasitic Infections
      • 11.3.2.1. Malaria
      • 11.3.2.2. Schistosomiasis
      • 11.3.2.3. Toxoplasmosis
    • 11.3.3. Viral Infections
      • 11.3.3.1. Hepatitis
      • 11.3.3.2. HIV
      • 11.3.3.3. Influenza
  • 11.4. Neurological
    • 11.4.1. Alzheimer's Disease
    • 11.4.2. Multiple Sclerosis
    • 11.4.3. Parkinson's Disease
  • 11.5. Oncology
    • 11.5.1. Breast Cancer
    • 11.5.2. Colorectal Cancer
    • 11.5.3. Lung Cancer
    • 11.5.4. Prostate Cancer

12. Multiplex Detection Immunoassays Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multiplex Detection Immunoassays Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multiplex Detection Immunoassays Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Merck KGaA
    • 15.3.3. Bio-Rad Laboratories, Inc.
    • 15.3.4. Becton, Dickinson and Company
    • 15.3.5. PerkinElmer, Inc.
    • 15.3.6. Luminex Corporation
    • 15.3.7. QIAGEN N.V.
    • 15.3.8. Bio-Techne Corporation
    • 15.3.9. Meso Scale Diagnostics, LLC
    • 15.3.10. Olink Proteomics AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MULTIPLEX DETECTION IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MULTIPLEX DETECTION IMMUNOASSAYS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTIPLEX DETECTION IMMUNOASSAYS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL MULTIPLEX